Home/Pipeline/APN-sEVs

APN-sEVs

Obesity and Type 2 Diabetes

Pre-clinicalActive

Key Facts

Indication

Obesity and Type 2 Diabetes

Phase

Pre-clinical

Status

Active

Company

Ciloa Bio

About Ciloa Bio

Ciloa Bio is a private, preclinical-stage biotech founded in 2016 and based in Montpellier, France. The company has developed a proprietary platform, EVENGI, for engineering small extracellular vesicles (sEVs) to carry therapeutic payloads, with a lead program (APN-sEVs) targeting obesity and type 2 diabetes. Ciloa has secured significant non-dilutive funding, including a recent €6.5 million grant from France 2030, and engages in strategic partnerships to advance its pipeline in metabolic diseases, vaccines, and oncology.

View full company profile

Therapeutic Areas

Metabolic Diseases Oncology Infectious Disease Rare Diseases Age-related Illnesses

Other Obesity and Type 2 Diabetes Drugs

Drug	Company	Phase	Status
CK-0045	Cytoki Pharma	Phase 2	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active